Simultaneous Inhibitory Effects of All-Trans Astaxanthin on Acetylcholinesterase and Oxidative Stress

Alzheimer´s disease is a global neurodegenerative health concern. To prevent the disease, the simultaneous inhibition of acetylcholinesterase and oxidative stress is an efficient approach. In this study, the inhibition effect of all-trans astaxanthin mainly from marine organisms on acetylcholinesterase and oxidative stress was evaluated by a chemical-based method in vitro and cell assay model. The results show that all-trans astaxanthin was a reversible competitive inhibitor and exhibited a strong inhibition effect with half inhibitory concentration (IC50 value) of 8.64 μmol/L. Furthermore, all-trans astaxanthin inhibited oxidative stress through reducing malondialdehyde content and increasing the activity of superoxide dismutase as well as catalase. All-trans astaxanthin could induce the changes of the secondary structure to reduce acetylcholinesterase activity. Molecular-docking analysis reveals that all-trans astaxanthin prevented substrate from binding to acetylcholinesterase by occupying the space of the active pocket to cause the inhibition. Our finding suggests that all-trans astaxanthin might be a nutraceutical supplement for Alzheimer´s disease prevention.

[1]  H. Wahab,et al.  Potential Anti-Acetylcholinesterase Activity of Cassia timorensis DC. , 2020, Molecules.

[2]  Yan-gang Cao,et al.  Alkaloids and lignans with acetylcholinesterase inhibitory activity from the flower buds of Magnolia biondii Pamp , 2020 .

[3]  Xinjun Yu,et al.  Effect of Quercetin on PC12 Alzheimer's Disease Cell Model Induced by Aβ25-35 and Its Mechanism Based on Sirtuin1/Nrf2/HO-1 Pathway , 2020, BioMed research international.

[4]  Junmei Wang,et al.  End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. , 2019, Chemical reviews.

[5]  Hanwen Sun,et al.  Spectroscopic investigation on the interaction characteristics and inhibitory activities between baicalin and acetylcholinesterase , 2018, Medicinal Chemistry Research.

[6]  M. Barron,et al.  Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[7]  B. van Ravenzwaay,et al.  Safety assessment of [3S, 3'S]-astaxanthin--Subchronic toxicity study in rats. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[8]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[9]  N. Chandel,et al.  ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.

[10]  Gokare A. Ravishankar,et al.  Astaxanthin: Sources, Extraction, Stability, Biological Activities and Its Commercial Applications—A Review , 2014, Marine drugs.

[11]  Alin Ciobica,et al.  The oxidative stress hypothesis in Alzheimer's disease. , 2013, Psychiatria Danubina.

[12]  Baolu Zhao,et al.  Oxidative Stress and the Pathogenesis of Alzheimer's Disease , 2013, Oxidative medicine and cellular longevity.

[13]  V. Vasić,et al.  Send Orders of Reprints at Reprints@benthamscience.net Acetylcholinesterase Inhibitors: Pharmacology and Toxicology , 2022 .

[14]  Juan-juan Wang,et al.  Hypoglycemic effect of astaxanthin from shrimp waste in alloxan-induced diabetic mice , 2012, Medicinal Chemistry Research.

[15]  J. Os,et al.  Cost of disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.

[16]  Xingshu Li,et al.  Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors. , 2011, Bioorganic & medicinal chemistry.

[17]  Alexander M. Wolf,et al.  Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. , 2010, The Journal of nutritional biochemistry.

[18]  D. Butterfield,et al.  Oxidatively modified proteins in Alzheimer’s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis , 2009, Acta Neuropathologica.

[19]  F. Pashkow,et al.  Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. , 2008, The American journal of cardiology.

[20]  Alzheimer’s Association,et al.  2008 Alzheimer’s disease facts and figures , 2008, Alzheimer's & Dementia.

[21]  S. Talbot,et al.  Investigation of the mechanism of enhanced effect of EGCG on huperzine A's inhibition of acetylcholinesterase activity in rats by a multispectroscopic method. , 2008, Journal of agricultural and food chemistry.

[22]  P. Eyer,et al.  Kinetic analysis of reactivation and aging of human acetylcholinesterase inhibited by different phosphoramidates. , 2007, Biochemical pharmacology.

[23]  Peter J Houghton,et al.  Acetylcholinesterase inhibitors from plants. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[24]  Vildan Alptüzün,et al.  Targeting acetylcholinesterase to treat neurodegeneration , 2007, Expert opinion on therapeutic targets.

[25]  L. Goya,et al.  Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  F. J. Luque,et al.  Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. , 2005, Journal of medicinal chemistry.

[27]  N. Kolla,et al.  Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. , 2005, Journal of psychiatry & neuroscience : JPN.

[28]  J. Oliveira,et al.  Superoxide dismutase, catalase and peroxidase activities do not confer protection against oxidative damage in salt-stressed cowpea leaves. , 2004, The New phytologist.

[29]  S. Mandel,et al.  Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. , 2004, The Journal of nutritional biochemistry.

[30]  P. Clarkson,et al.  Oxidative stress, exercise, and antioxidant supplementation. , 2003, Toxicology.

[31]  Miguel Olaizola,et al.  Haematococcus astaxanthin: applications for human health and nutrition. , 2003, Trends in biotechnology.

[32]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[33]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[34]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[35]  L. Skibsted,et al.  Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants , 1997, FEBS letters.

[36]  I. Enyedy,et al.  Probing the Active Site of Acetylcholinesterase by Molecular Dynamics of Its Phosphonate Ester Adducts , 1996 .

[37]  G. Kleywegt,et al.  Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. , 1995, Structure.

[38]  G. Benzi,et al.  Authors' response to commentaries , 1995, Neurobiology of Aging.

[39]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[40]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[41]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[42]  T. Arndt.  Crystal , 2019, Springer Reference Medizin.

[43]  M. De Hert,et al.  Cost of disorders of the brain in Europe. , 2006, European journal of neurology.

[44]  A. Doig,et al.  Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. , 2000, The Journal of biological chemistry.

[45]  W R Markesbery,et al.  Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.